Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1981 Jul;12(1):39–45. doi: 10.1111/j.1365-2125.1981.tb01852.x

The pharmacokinetics of nortriptyline in patients with chronic renal failure.

S Dawlilng, K Lynn, R Rosser, R Braithwaite
PMCID: PMC1401753  PMID: 7248140

Abstract

1 The pharmacokinetics of single oral doses of nortriptyline were studied in twenty patients with chronic renal failure, eight of whom were receiving treatment with haemodialysis. 2 The median nortriptyline half-life was 25.2 h (range 14.5-140.0 h) and the median nortriptyline clearance was 32.3 l/h (range 8.1-122.0 l/h). 3 No differences were observed between the dialysed and non-dialysed groups. 4 Comparisons of nortriptyline half-life and clearance between the patients and groups of physically healthy subjects revealed no significant differences. 5 There was no significant linear correlation between age and either of these measurements. In the twelve patients not receiving haemodialysis there was no correlation between nortriptyline clearance and glomerular filtration rate. 6 Chronic renal failure is not associated with a significant alteration in nortriptyline metabolism as measured by its half-life or clearance, but the drug should nonetheless be used with caution, and monitored whenever possible. However, the marked inter-individual differences observed in nortriptyline half-life and clearance in patients with chronic renal failure may not be solely responsible for their unpredictable response to tricyclic antidepressant therapy, and other possible contributory factors are discussed.

Full text

PDF
43

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanderson B. Pharmacokinetics of nortriptyline in man after single and multiple oral doses: the predictability of steady-state plasma concentrations from single-dose plasma-level data. Eur J Clin Pharmacol. 1972 Mar;4(2):82–91. doi: 10.1007/BF00562502. [DOI] [PubMed] [Google Scholar]
  2. Alexanderson B. Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics: a study in twins. Eur J Clin Pharmacol. 1973 Jun;6(1):44–53. doi: 10.1007/BF00561800. [DOI] [PubMed] [Google Scholar]
  3. Asberg M., Crönholm B., Sjöqvist F., Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J. 1971 Aug 7;3(5770):331–334. doi: 10.1136/bmj.3.5770.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Asberg M. Plasma nortriptyline levels--relationship to clinical effects. Clin Pharmacol Ther. 1974 Jul;16(1):215–229. [PubMed] [Google Scholar]
  5. Bertilsson L., Mellström B., Sjöqvist F. Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. Life Sci. 1979 Oct 8;25(15):1285–1292. doi: 10.1016/0024-3205(79)90393-x. [DOI] [PubMed] [Google Scholar]
  6. Borgå O., Azarnoff D. L., Forshell G. P., Sjöqvist F. Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol. 1969 Sep;18(9):2135–2143. doi: 10.1016/0006-2952(69)90318-9. [DOI] [PubMed] [Google Scholar]
  7. Braithwaite R., Montgomery S., Dawling S. Nortriptyline in depressed patients with high plasma levels. II. Clin Pharmacol Ther. 1978 Mar;23(3):303–308. doi: 10.1002/cpt1978233303. [DOI] [PubMed] [Google Scholar]
  8. Brinkschulte M., Breyer-Pfaff U. Binding of tricyclic antidepressants and perazine to human plasma. Methodology and findings in normals. Naunyn Schmiedebergs Arch Pharmacol. 1979 Jul;308(1):1–7. doi: 10.1007/BF00499712. [DOI] [PubMed] [Google Scholar]
  9. Buchanan D. C., Abram H. S., Wells C., Teschan P. Psychosis and pseudo dementia associated with hemodialysis. Int J Psychiatry Med. 1977;8(1):85–97. doi: 10.2190/28gq-f6x0-6ha6-d4rw. [DOI] [PubMed] [Google Scholar]
  10. Cooper T. B., Simpson G. M. Prediction of individual dosage of nortriptyline. Am J Psychiatry. 1978 Mar;135(3):333–335. doi: 10.1176/ajp.135.3.333. [DOI] [PubMed] [Google Scholar]
  11. Cramond W. A., Knight P. R., Lawrence J. R., Higgins B. A., Court J. H., MacNamara F. M., Clarkson A. R., Miller C. D. Psychological aspects of the management of chronic renal failure. Br Med J. 1968 Mar 2;1(5591):539–543. doi: 10.1136/bmj.1.5591.539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dawling S., Braithwaite R. A. Simplified method for monitoring tricyclic antidepressant therapy using gas--liquid chromatography with nitrogen detection. J Chromatogr. 1978 Nov 1;146(3):449–456. doi: 10.1016/s0378-4347(00)81203-7. [DOI] [PubMed] [Google Scholar]
  13. Dawling S., Crome P., Braithwaite R. A., Lewis R. R. Nortriptyline therapy in elderly patients: dosage prediction after single dose pharmacokinetic study. Eur J Clin Pharmacol. 1980 Aug;18(2):147–150. doi: 10.1007/BF00561582. [DOI] [PubMed] [Google Scholar]
  14. Dawling S., Crome P., Braithwaite R. Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young healthy volunteers. Clin Pharmacokinet. 1980 Jul-Aug;5(4):394–401. doi: 10.2165/00003088-198005040-00007. [DOI] [PubMed] [Google Scholar]
  15. Dettli L., Spring P., Habersang R. Drug dosage in patients with impaired renal function. Postgrad Med J. 1970 Oct;(Suppl):32–35. [PubMed] [Google Scholar]
  16. Farmer C. J., Snowden S. A., Parsons V. The prevalence of psychiatric illness among patients on home haemodialysis. Psychol Med. 1979 Aug;9(3):509–514. doi: 10.1017/s0033291700032062. [DOI] [PubMed] [Google Scholar]
  17. Gram L. F., Overo K. F. First-pass metabolism of nortriptyline in man. Clin Pharmacol Ther. 1975 Sep;18(3):305–314. doi: 10.1002/cpt1975183305. [DOI] [PubMed] [Google Scholar]
  18. Kragh-Sorensen P., Hansen C. E., Baastrup P. C., Hvidberg E. F. Self-inhibiting action of nortriptylin's antidepressive effect at high plasma levels: a randomized double-blind study controlled by plasma concentrations in patients with endogenous depression. Psychopharmacologia. 1976 Feb 2;45(3):305–312. doi: 10.1007/BF00421145. [DOI] [PubMed] [Google Scholar]
  19. Kragh-Sørensen P. Correlation between plasma levels of nortriptyline and clinical effects. Commun Psychopharmacol. 1978;2(5):451–456. [PubMed] [Google Scholar]
  20. Levy G. Pharmacokinetics in renal disease. Am J Med. 1977 Apr;62(4):461–465. doi: 10.1016/0002-9343(77)90397-7. [DOI] [PubMed] [Google Scholar]
  21. McCormick M., Navarro V. Prevalence of chronic renal failure and access to dialysis. Int J Epidemiol. 1973 Autumn;2(3):247–255. doi: 10.1093/ije/2.3.247. [DOI] [PubMed] [Google Scholar]
  22. Montgomery S. A., McAuley R., Montgomery D. B., Braithwaite R. A., Dawling S. Dosage adjustment from simple nortriptyline spot level predictor tests in depressed patients. Clin Pharmacokinet. 1979 Mar-Apr;4(2):129–136. doi: 10.2165/00003088-197904020-00005. [DOI] [PubMed] [Google Scholar]
  23. Potter W. Z., Calil H. M., Manian A. A., Zavadil A. P., Goodwin F. K. Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity. Biol Psychiatry. 1979 Aug;14(4):601–613. [PubMed] [Google Scholar]
  24. Reidenberg M. M. The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. Am J Med. 1977 Apr;62(4):466–470. doi: 10.1016/0002-9343(77)90398-9. [DOI] [PubMed] [Google Scholar]
  25. Reidenberg M. M. The biotransformation of drugs in renal failure. Am J Med. 1977 Apr;62(4):482–485. doi: 10.1016/0002-9343(77)90401-6. [DOI] [PubMed] [Google Scholar]
  26. Tyler H. R. Neurologic disorders in renal failure. Am J Med. 1968 May;44(5):734–748. doi: 10.1016/0002-9343(68)90255-6. [DOI] [PubMed] [Google Scholar]
  27. Wilkinson G. R., Shand D. G. Proceedings: Presystemic hepatic elimination. Acta Pharm Suec. 1974 Dec;11(6):648–649. [PubMed] [Google Scholar]
  28. Ziegler V. E., Clayton P. J., Taylor J. R., Tee B., Biggs J. T. Nortriptyline plasma levels and therapeutic response. Clin Pharmacol Ther. 1976 Oct;20(4):458–463. doi: 10.1002/cpt1976204458. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES